Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative brain disorder
with no current cure. One of the important therapeutic approaches of AD is the inhibition of β …

The incidence of Alzheimer's disease (AD) is growing every day and finding an effective
treatment is becoming more vital. Amyloid-β (Aβ) has been the focus of research for several …

Amyloid beta peptide (Aβ) is produced through the proteolytic processing of a
transmembrane protein, amyloid precursor protein (APP), by β-and γ-secretases. Aβ …

Alzheimer's disease (AD) is the most common form of dementia in the elderly, and affects
millions of people worldwide. As the number of AD cases continues to increase in both …

One of the grand challenges of biophysical chemistry is to understand the principles that
govern protein misfolding and aggregation, which is a highly complex process that is …

The search for therapeutic agents that bind specifically to precursor protein conformations
and inhibit amyloid assembly is an important challenge. Identifying such inhibitors is difficult …

Alzheimer's disease (AD) is a disabling and highly prevalent neurodegenerative condition,
for which there are no effective therapies. Soluble oligomers of the amyloid-β peptide (AβOs) …

Alzheimer disease is characterized by the abnormal aggregation of amyloid β peptide into
extracellular fibrillar deposits known as amyloid plaques. Soluble oligomers have been …

Oligomeric intermediates are non-fibrillar polypeptide assemblies that occur during amyloid
fibril formation and that are thought to underlie the aetiology of amyloid diseases, such as …

Irisin, the circulating peptide originating from fibronectin type III domain-containing protein 5
(FNDC5), is mainly expressed by muscle fibers under peroxisome proliferator-activated …